Trial Profile
Multicenter, Randomized Trial to Evaluate Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment vs Endocrine Alone, in Postmenopausal With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fulvestrant; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms LEA
- 02 Jul 2019 Results of pooled-analysis (n=749) from two randomized trials (NCT00545077 and NCT00601900) published in the European Journal of Cancer.
- 06 Jun 2017 Results of pooled-analysis (n=749) using data from two randomized trials (LEA and CALGB 40503), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 11 Oct 2016 Results evaluating role of two biomarkers, ACE and CXCL10 as prognostic and/or predictive biomarkers of benefit to bevacizumab in the first line metastatic disease presented at the 41st European Society for Medical Oncology Congress